Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/dgjigroup/www/www/inc/parsefile.php on line 7
Dragon Jade International
Location: Dragon Jade International Limited » Press Releases » Dragon Jade International Announces Exclusive Negotiation For SleepMate

Press Releases


  • It becomes abundantly clear that traditional Chinese medicines (TCM) is going to be the next modality and prescribed TCM formulas will be viewed as powerful therapeutic cures. Dragon Jade pioneering endeavors in promoting better access and broader use of TCM will definitely be paid off and return of investments should be remarkable.

  • Dragon Jade in-depth understanding of how to carry out biomedical experimentation, clinical traits, systematic reviews and sampled surveys will surely help its selected traditional Chinese medicines partner companies to meet the western scientific disciplines of medicines or healthcare products.

  • Dragon Jade has extensive know- how techniques to implement and comply with the prescribed codes of practices and relevant laws and ordinances. These merits will definitely attract generous funds and revenues in the near future for there are far too many TCM companies are eager to seek assistance to help them deal with the tough FDA regulatory regime.

  • read more....

    Dragon Jade International Announces Exclusive Negotiation For SleepMate

    Dragon Jade International Announces Exclusive Negotiation for SleepMate

    Hong Kong, January 5, 2015 -- Dragon Jade International Limited (OTCQB:DGJI) (the “Company”) announced today that it is negotiating for the exclusive licensing rights to SleepMate , a medical monitoring application device.

    The alliance, upon completion, will cover two major strategic initiatives:

    1.   Food and Drug Administration Approval

    Parties will collaborate on submitting a medical device submission for FDA clearance on the SleepMate product.  The SleepMate device is categorized as Lowest Risk device according to the FDA guidelines and can be submitted under a FDA fast-track process.

    2.   Exclusive Distribution of SleepMate Products

    Dragon Jade will be granted an exclusive license to represent and distribute all SleepMate products.  Dragon Jade will leverage on it’s proprietary medicinal resellers network to capitalize on marketing the FDA approved SleepMate brand.

    SleepMate was developed and manufactured by a Chinese technology company for the Chinese market.  The initial product is a blanket with sensors placed within it.  The sensors monitor heart rate, respiration rate, sleep quality and depth.  Data collected can be transmitted to smart phones or computers through Bluetooth and WIFI for analyzing to improve any dysfunctional sleeping patterns.

    The SleepMate product is particularly well suited for families wishing to monitor other family members.  By accessing the SleepMate health vital signs through an APP on their smart phones, we can improve the health standards at home now.


    The health monitoring device market is growing at a significant rate.  The global market is expected to reach $22,173.8 million by 2018 growing at a CAGR of 5.5% during the forecast period (2013–2018).   The driving factors of the monitoring market are due to the rise in aging population living alone and growing health awareness.


    About Dragon Jade International Ltd

    The Company is focused on identifying, developing and marketing the next generation of herbal and bio-technological discoveries that improve people's lives.


    Safe Harbor Statement

    This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as the Company "believes," "expects," "anticipates," "foresees," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.